EU/3/14/1299: Orphan designation for the treatment of systemic sclerosis
Table of contents
On 29 July 2014, orphan designation (EU/3/14/1299) was granted by the European Commission to Bayer Pharma AG, Germany, for riociguat for the treatment of systemic sclerosis.
The sponsorship was transferred to Bayer AG, Germany, in August 2017.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2019 on request of the Sponsor.
Treatment of systemic sclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: